- Trials with a EudraCT protocol (225)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
225 result(s) found for: Brain imaging examination.
Displaying page 7 of 12.
EudraCT Number: 2015-004214-14 | Sponsor Protocol Number: P311-201 | Start Date*: 2016-10-13 | ||||||||||||||||
Sponsor Name:Upsher-Smith Laboratories, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination with Lomustine (CCNU) in Subjects with Advanced Solid Tumors, with Subsequent Single Agent and Combination Phase 2 Cohorts f... | ||||||||||||||||||
Medical condition: Advanced Solid Tumors/Relapsed/Recurrent Glioblastoma Multiforme (GBM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005177-29 | Sponsor Protocol Number: EORTC 26052-22053 | Start Date*: 2006-11-10 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma | |||||||||||||
Medical condition: Patients with Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005549-17 | Sponsor Protocol Number: FAPI-MN-2020 | Start Date*: 2021-04-21 | |||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | |||||||||||||
Full Title: Role of [68Ga]Ga-FAPI PET/CT in oncological patients with doubtful or inconclusive findings at [18F]F-FDG PET/CT | |||||||||||||
Medical condition: oncological disease suspicion/ new diagnosis or with a previously treated tumour, with an inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT ima... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001876-32 | Sponsor Protocol Number: SLN360-002 | Start Date*: 2023-04-14 | ||||||||||||||||
Sponsor Name:Silence Therapeutics plc | ||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at... | ||||||||||||||||||
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) NL (Completed) SK (Completed) DK (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001291-56 | Sponsor Protocol Number: A8241021 | Start Date*: 2014-10-27 | ||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE | ||||||||||||||||||
Medical condition: HUNTINGTON’S DISEASE | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005724-10 | Sponsor Protocol Number: SPIHF-201 | Start Date*: 2016-06-07 | |||||||||||
Sponsor Name:Stealth BioTherapeutics Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart... | |||||||||||||
Medical condition: Stable Heart Failure with Reduced Ejection Fraction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001800-31 | Sponsor Protocol Number: GN39763 | Start Date*: 2018-04-06 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE | |||||||||||||
Medical condition: Alzheimer's Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DK (Completed) FI (Prematurely Ended) DE (Prematurely Ended) PL (Completed) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001411-39 | Sponsor Protocol Number: ABT-002 | Start Date*: 2018-09-04 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB | ||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005280-27 | Sponsor Protocol Number: AFF006A | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:AFFiRiS AG | |||||||||||||
Full Title: A randomized, controlled, parallel group, double-blind, multi-centre, phase IIb study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations of patients who participated in... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) SK (Completed) HR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001326-15 | Sponsor Protocol Number: RXDX-101-01 | Start Date*: 2014-10-15 | ||||||||||||||||
Sponsor Name:Ignyta Inc. | ||||||||||||||||||
Full Title: A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alter... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic solid tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000418-75 | Sponsor Protocol Number: TV5600-CNS-20007 | Start Date*: 2014-11-18 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients... | |||||||||||||
Medical condition: Huntington's Disease (HD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003928-23 | Sponsor Protocol Number: E2609-G000-301 | Start Date*: 2017-08-11 | |||||||||||||||||||||
Sponsor Name:Eisai Ltd. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease | |||||||||||||||||||||||
Medical condition: Early Alzheimer Disease including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001739-38 | Sponsor Protocol Number: TAK-831-2001 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000552-33 | Sponsor Protocol Number: LUMC_2012 | Start Date*: 2012-11-27 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: Adoptive T cell therapy plus vaccination in metastatic melanoma patients | ||
Medical condition: Metastasized melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002471-25 | Sponsor Protocol Number: BN40697(ISIS443139-CS2) | Start Date*: 2018-10-18 | |||||||||||
Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVES... | |||||||||||||
Medical condition: Early Manifest Huntington's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000954-86 | Sponsor Protocol Number: 107CS-5 | Start Date*: 2020-08-17 | ||||||||||||||||
Sponsor Name:Daehwa Pharmaceutical Co., Ltd. | ||||||||||||||||||
Full Title: A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients wit... | ||||||||||||||||||
Medical condition: Recurrent or metastatic HER2 negative Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Trial now transitioned) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001824-43 | Sponsor Protocol Number: DS1040-A-U103 | Start Date*: 2016-02-04 |
Sponsor Name:Daiichi Sankyo, Inc. | ||
Full Title: A Phase 1b/2, multi-center, double-blind (principal investigators and study subjects blinded, sponsor unblinded), placebo-controlled, randomized, single-ascending dose study to assess the safety, p... | ||
Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including acute ischemic stroke (A... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) GB (Completed) CZ (Completed) ES (Completed) SK (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000845-11 | Sponsor Protocol Number: TIRCON2012V1 | Start Date*: 2012-07-16 |
Sponsor Name:ApoPharma Inc. | ||
Full Title: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN) | ||
Medical condition: Pantothenate kinase-associated neurodegeneration (PKAN) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005755-20 | Sponsor Protocol Number: ALZ-801-AD301 | Start Date*: 2021-06-21 | |||||||||||
Sponsor Name:Alzheon, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype | |||||||||||||
Medical condition: Early Alzheimer’s Disease (AD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) NL (Completed) ES (Completed) CZ (Completed) IS (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
